Another study investigating the role of exosomes in breast cancer treatment indicated that the utilization of mesothelin (MSLN)-targeted CAR-T cell-originated exosomes successfully inhibited the growth of MSLN-positive cancer cells in triple-negative breast cancer (Yang et al., 2021). This evidence concerns the gene MSLN and triple-negative breast carcinoma.